Neuphoria Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Neuphoria Therapeutics.
Neuphoria Therapeutics Overview
About Neuphoria Therapeutics
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
Founded
1996
HQ
Employees
24
Website
Financials (LTM)
EV
$2M
Valuation Multiples
Start free trial
Neuphoria Therapeutics Financials
Neuphoria Therapeutics reported last 12-month revenue of - and negative EBITDA of ($16M).
In the same LTM period, Neuphoria Therapeutics generated - in gross profit, ($16M) in EBITDA losses, and had net loss of ($19M).
Neuphoria Therapeutics P&L
In the most recent fiscal year, Neuphoria Therapeutics reported revenue of $16M and EBITDA of ($166K).
Neuphoria Therapeutics is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (1%), and net margin of (2%).
Financial data powered by Morningstar, Inc.
Neuphoria Therapeutics Stock Performance
Neuphoria Therapeutics has current market cap of $21M, and enterprise value of $2M.
Neuphoria Therapeutics' stock price is $3.88.
Neuphoria Therapeutics has an EPS (earnings per share) of $-0.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2M | $21M | -1.8% | - | - | - | $-0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeuphoria Therapeutics Valuation Multiples
Neuphoria Therapeutics trades at 0.1x EV/Revenue multiple, and (0.1x) EV/EBITDA.
Neuphoria Therapeutics Financial Valuation Multiples
As of August 3, 2026, Neuphoria Therapeutics has market cap of $21M and EV of $2M.
Neuphoria Therapeutics has a P/E ratio of (1.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Neuphoria Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Neuphoria Therapeutics Margins & Growth Rates
Neuphoria Therapeutics decreased revenue by 100% but EBITDA grew by 9642% in the last fiscal year.
In the most recent fiscal year, Neuphoria Therapeutics reported gross margin of 100%, EBITDA margin of (1%), and net margin of (2%).
Neuphoria Therapeutics Margins
Neuphoria Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Neuphoria Therapeutics Operational KPIs
Neuphoria Therapeutics' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.7M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Neuphoria Therapeutics Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Neuphoria Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Neuphoria Therapeutics
| When was Neuphoria Therapeutics founded? | Neuphoria Therapeutics was founded in 1996. |
| Where is Neuphoria Therapeutics headquartered? | Neuphoria Therapeutics is headquartered in United States. |
| How many employees does Neuphoria Therapeutics have? | As of today, Neuphoria Therapeutics has over 24 employees. |
| Is Neuphoria Therapeutics publicly listed? | Yes, Neuphoria Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Neuphoria Therapeutics? | Neuphoria Therapeutics trades under NEUP ticker. |
| When did Neuphoria Therapeutics go public? | Neuphoria Therapeutics went public in 2021. |
| Who are competitors of Neuphoria Therapeutics? | Neuphoria Therapeutics main competitors include |
| What is the current market cap of Neuphoria Therapeutics? | Neuphoria Therapeutics' current market cap is $21M. |
| What is the current revenue growth of Neuphoria Therapeutics? | Neuphoria Therapeutics revenue growth (vs. last FY) is (100%). |
| What is the current EV/Revenue multiple of Neuphoria Therapeutics? | Current revenue multiple of Neuphoria Therapeutics is 0.1x. |
| Is Neuphoria Therapeutics profitable? | No, Neuphoria Therapeutics is not profitable. |
| What is the current EBITDA of Neuphoria Therapeutics? | Neuphoria Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Neuphoria Therapeutics? | Current EBITDA multiple of Neuphoria Therapeutics is (0.1x). |
| How many companies Neuphoria Therapeutics has acquired to date? | Neuphoria Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Neuphoria Therapeutics has invested to date? | Neuphoria Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
Lists including Neuphoria Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.